<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01373801</url>
  </required_header>
  <id_info>
    <org_study_id>sor517911ctil</org_study_id>
    <nct_id>NCT01373801</nct_id>
  </id_info>
  <brief_title>Hemcon© Bandage for Postpartum Bleeding Due to the Multiple Vaginal Lacerations</brief_title>
  <official_title>THE EFFICACY AND SAFETY OF HEMCON© BANDAGE FOLLOWING SURGICAL REPAIR IN MANAGEMENT OF POSTPARTUM BLEEDING DUE TO THE MULTIPLE VAGINAL LACERATIONS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Soroka University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>HemCon Medical Technologies, Inc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Soroka University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to assess the safety and efficacy of the HemCon GuardaCareXR
      compared to standard bandaging in subjects with post partum hemorrhage as a result of
      cervical and vaginal lacerations. The primary endpoint will be a cessation of bleeding at 30
      minutes after insertion of the dressing.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2011</start_date>
  <primary_completion_date type="Anticipated">July 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cessation of bleeding after a 30 minutes</measure>
    <time_frame>30 minutes</time_frame>
    <description>The primary endpoint is a cessation of bleeding after a 30 minute period. Evaluation of bleeding will be performed by an independent evaluator, who will determine if the bleeding has stopped.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety composite endpoint</measure>
    <time_frame>7 days</time_frame>
    <description>Rate of the safety composite (any of the following):
Anaphylaxis or allergic reaction
Recurrent Hospitalization
Serious adverse events
Need for the repeated surgical intervention
Need for blood products transfusion
Local Infection In addition individual rates of the components will be reported</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device Success</measure>
    <time_frame>6 hours</time_frame>
    <description>Device success defined as a cessation of bleeding at 6 hours using only the allocated device.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedural success</measure>
    <time_frame>6 hours</time_frame>
    <description>Procedural success defined as a cessation of bleeding at 6 hours.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">85</enrollment>
  <condition>Postpartum Bleeding</condition>
  <condition>Vaginal Lacerations</condition>
  <condition>Cervical Lacerations</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>GuardaCare</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>The HemCon GuardaCare</intervention_name>
    <description>The HemCon GuardaCare (HemCon Medical Technologies Inc., Portland, OR) is a hemostatic dressing made of chitosan, a complex carbohydrate derived from chitin from shellfish and is designed as a hemostatic dressing, and a topical antimicrobial dressing. GuardaCare contains no pro-clotting agents, providing a safe and localized hemostatic solution and is latex free and sterile.</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>GuardaCare</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Control</intervention_name>
    <description>Standard packing gauze roll bandage.</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed Informed Consent

          2. Age≥18 year

          3. Two or more 2nd degree vaginal lacerations , 3rd degree vaginal lacerations and
             cervical laceration

        Exclusion Criteria:

          1. Subjects undertaking anticoagulation treatment

          2. Pre-existing coagulopathy

          3. Massive uncontrolled bleeding requiring blood transfusions/urgent vascular surgery.

          4. Systolic blood pressure &lt;90mmHg

          5. Shellfish allergy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arnon Wiznitzer, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Soroka University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Victor Novack, M.D. PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Soroka University Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Arnon Wiznitzer, MD</last_name>
    <phone>972-8-6400774</phone>
    <email>arnonw@clalit.org.il</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ayala Dvir, MsC</last_name>
    <phone>972-8-6244245</phone>
    <email>ayaladv@clalit.org.il</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>OB\GYN Soroka University Medical Center</name>
      <address>
        <city>Beer Sheva</city>
        <zip>84101</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ayala Dvir, MsC</last_name>
      <phone>972-8-62444245</phone>
      <email>ayaladv@clalit.org.il</email>
    </contact>
    <investigator>
      <last_name>Arnon Wiznitzer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>April 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 13, 2011</study_first_submitted>
  <study_first_submitted_qc>June 14, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 15, 2011</study_first_posted>
  <last_update_submitted>August 9, 2011</last_update_submitted>
  <last_update_submitted_qc>August 9, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 10, 2011</last_update_posted>
  <responsible_party>
    <name_title>Prof. Arnon Wiznitzer, Head of Obstetrics and Gynecology Division</name_title>
    <organization>Soroka University Medical Center</organization>
  </responsible_party>
  <keyword>Postpartum women, after surgical repair of vaginal and cervical lacerations</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Lacerations</mesh_term>
    <mesh_term>Postpartum Hemorrhage</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

